Cerebrospinal fluid viral replication and burden of resistance in three HIV-1-infected people taking Ibalizumab with multiple drug class-wide resistance-Reference-Cited by-同舟云学术

Cerebrospinal fluid viral replication and burden of resistance in three HIV-1-infected people taking Ibalizumab with multiple drug class-wide resistance

Published:2020-09-14 Issue:14 Volume:34 Page:2152-2155
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Muccini Camilla,Spagnuolo Vincenzo,Canetti Diana,Bigoloni Alba,Cernuschi Massimo,Franzin Michela,Sampaolo Michela,Castagna Antonella

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference8 articles.

1. Ibalizumab: a review in multidrug-resistant HIV-1 infection;Blair;Drugs,2020

2. Ibalizumab, a novel monoclonal antibody for the management of multidrug-resistant HIV-1 infection;Beccari;Antimicrob Agents Chemother,2019

3. Ibalizumab targeting CD4 receptors, an emerging molecule in HIV therapy;Iacob;Front Microbiol,2017

4. Phase 3 study of ibalizumab for multidrug-resistant HIV-1;Emu;N Engl J Med,2018

5. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies;Canducci;AIDS,2009

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment‐experienced and/or have multidrug‐resistant HIV‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-05

2. HIV drug resistance in various body compartments;Current Opinion in HIV and AIDS;2022-07